Structural & Congenital Heart Disease

Both severe and moderate aortic stenosis, when left untreated, were associated with poor long-term survival in a large-scale study of Australian heart patients.

Edwards Lifesciences announced Nov. 6 that it had received expanded CE mark approval in Europe for the use of its SAPIEN 3 transcatheter heart valve, a tool designed to facilitate TAVI in patients who don’t want to undergo open-heart surgery.

Children’s hospitals across the U.S. are backing a national effort by the Pediatric Congenital Heart Association to improve transparency in the reporting of cardiac surgical outcomes.

An increase in public reporting of aortic valve surgery outcomes has been tied to a decrease in AVR access for patients with infective endocarditis—the unintended consequence of a push for greater transparency in healthcare.

Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.

Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

Medtronic announced Sept. 27 that it had received FDA approval to launch an early feasibility study for its Intrepid TMVR system using a minimally invasive transfemoral access approach.

The incidence of aborted procedures during transcatheter aortic valve replacement is falling, according to work published in JACC: Cardiovascular Interventions, but centers with low institutional TAVR volume still struggle to keep up with bigger hospitals’ success.

The need for surgical bailout in heart patients undergoing TAVR is low, according to research published in JACC: Cardiovascular Interventions, but when it is performed outcomes are poor, reaching 50% mortality at 30 days.

People who currently take or have recently taken fluoroquinolones face higher odds of aortic and mitral regurgitation, according to a report out of Canada.

The problem is fixable, but it will take hard work, says one Duke University researcher. And cardiologists could be the key.